- 1.
Kreft i Norge 1996. Oslo: Kreftregisteret, 1999.
- 2.
Harvei S. Prostatakreftens epidemiologi. Tidsskr Nor Lægeforen 1999; 119: 3589 – 94.
- 3.
Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumour marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907 – 23.
- 4.
Hara M, Koyanogi Y, Inoue T, Fukuyara T. Some physiochemical characteristics of gamma seminoprotein, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. J Legal Med 1971; 25: 322.
- 5.
Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159 – 63.
- 6.
Lilja H. A kallikrein like serine protease in prostatic fluid cleaves the predominant seminal vesical protein. J Clin Invest 1985; 76: 1899 – 903.
- 7.
Brawer MK, Rennels MA, Nagle RB, Schifman R, Gaines JA. Serum prostate-specific and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 1989; 92: 760 – 64.
- 8.
Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980; 40: 2428 – 32.
- 9.
McCormack RT, Rittenhaus HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE. Molecular forms of prostate spesific antigen and the human kallikrein gene family. A new era. Urology 1995; 45: 729 – 44.
- 10.
Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ. Hormone regulation of prostate specific antigen messenger RNA in human prostatic adenocarcinoma cell-line LNCaP. Cancer Res 1991; 51: 3748 – 52.
- 11.
Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate spesific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31 – 7.
- 12.
Roehrborn CG, Oesterling JE, Olsson PJ, Padley RJ, HYCAT Investigator Group. Hytrin Community Assessment Trial: serial prostate spesific antigen measurements in men with clinically benign prostatic hyperplasia during a 12 month placebo controlled study with terazosin. Urology 1997; 50: 556.
- 13.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909 – 16.
- 14.
Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate spesific antigen concentration. Urology 1996; 47: 511.
- 15.
Angelsen A, Hole A, Lundmo P, Romslo I. PSA and digital rectal examination. Clin Chem 1992; 38: 782.
- 16.
Dalton DL. Elevated serum prostate spesific antigen due to acute bacterial prostatitis. Urology 1989; 33: 465.
- 17.
Semjonow A, Roth S, Hamm M, Rathert P. Non-traumatic elevation of prostate spesific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass. J Urol 1995; 155: 295 – 6.
- 18.
Catalona WJ, Smith DS, Ratliff TJ, Dodds KM, Coplen DE, Yuan JJJ et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156 – 61.
- 19.
Fosså SD, Eri LM. Norske legers rutiner for opportunistisk screening for prostatakreft. Tidsskr Nor Lægeforen 1999; 119: 3572 – 6.
- 20.
Johansen TEB. PSA-basert screening for prostatakreft. Tidsskr Nor Lægeforen 1999; 119: 3550.
- 21.
Carter HB, Pearson JE, Metter J, Brandt LJ, Chan DW, Andres R et al. Longitudinal evaluation of prostate spesific antigen levels in men with and without prostate diseases. JAMA 1992; 267: 2215 – 20.
- 22.
Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815 – 6.
- 23.
Kabalin JN, McNeal JE, Johnston IM, Stamey TA. Serum PSA and the biologic progression of prostate cancer. Urology 1995; 46: 65 – 70.
- 24.
Partin AW, Carter HB, Chan DW, Epstein JL, Oesterling JE, Rock RC et al. Prostate specific antigen in the staging of localised prostate cancer: influence of tumour differentiation, tumour volume and benign prostatic hyperplasia. J Urol 1990; 143: 747 – 52.
- 25.
Seaman E, Whang IS, Olsson CA, Catz A, Cooner WH, Benson NC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993; 20: 653.
- 26.
Djavan B, Marberger M, Zlotta A, Schulman CC. PSA, f/t-PSA, PSAD, PSA-TZ and PSA velocity for prostate cancer prediction: a multivariate analysis. J Urol 1998; 159: 235A.
- 27.
Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, German CJ, Panzer LA et al. Serum prostate spesific antigen in a community based population of healthy men: establishment of age specific reference ranges. JAMA 1993; 270: 860 – 4.
- 28.
Reissigl A, Pointner J, Horninger W, Ennemoser O, Strasser H, Klocker H et al. Comparison of different prostate-specific antigen cut points for early detection of prostate cancer: results of a large screening population. Urology 1995; 46: 662 – 5.
- 29.
Borer JG, Serman J, Solomom MC, Plawker MW, Misseri R, Crowley AR et al. Age specific reference ranges for prostate-specific antigen and digital rectal examination may not safely eliminate further diagnostic procedures. J Urol 1996; 155: 48A.
- 30.
Etzioni R, Shen Y, Petteway JC, Brawer MK. Age specific PSA: a reassessment. Prostate 1996; 7: 70 – 7.
- 31.
Stenmann UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O. A complex between prostate specific antigen and alfa-1-antichymotrypsine is the major form of prostate specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222 – 6.
- 32.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542 – 7.
- 33.
Sokoll LJ, Bruzek DJ, Cox JL, Partin AW, Chan DW, Morris DL et al. Is complexed PSA alone clinical useful? J Urol 1998; 159: 234A.
- 34.
Meyer GE, Brawer MK, Letran JL, Ransom SD, Allard WJ. Alfa-1-antichymotrypsin complex PSA in men undergoing prostate biopsy offers significant advantage for the detection of carcinoma over total PSA free to total PSA. J Urol 1998; 159: 72A.
- 35.
Stamey TA, Yemoto CE. Examination of 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000; 163: 119 – 26.
- 36.
Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate-specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159: 5 – 12.
- 37.
Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localised prostate cancer. J Urol 1993; 150: 110 – 4.
- 38.
Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localised prostate cancer. Sem Urol Oncol 1998; 16: 100 – 5.
- 39.
Stein A, deKernion JB, Dory F. Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. Br J Urol 1991; 67: 626 – 31.
- 40.
Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate spesific antigen following anatomical radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395 – 406.
- 41.
ASTROCP American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Rad Oncol Biol Phys 1997; 37: 1035.
- 42.
Zagars GK, Sherman NE, Babaian RJ. Prostate specific antigen and external beam radiation therapy in prostate cancer. Cancer 1991; 67: 412 – 20.
- 43.
Leo ME, Bilhartz DL, Bergstralh EK, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991; 145: 802.
- 44.
Stamey TA, Kabalin JN, Ferrari M, Young N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Antiandrogen treated patients. J Urol 1989; 141: 1088.
- 45.
Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery – what we have learned and where we are going. J Urol 1999; 162: 293 – 306.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.